Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;6(4):420-427.
doi: 10.1177/23969873211059479. Epub 2021 Nov 12.

A case series of cerebral venous thrombosis as the first manifestation of homocystinuria

Affiliations

A case series of cerebral venous thrombosis as the first manifestation of homocystinuria

Antonio Ochoa-Ferraro et al. Eur Stroke J. 2021 Dec.

Abstract

Background: Cerebral venous thrombosis (CVT) is an important cause of stroke particularly in younger patients and potentially fatal if diagnosis is delayed. The presentation of symptoms is highly variable and consequently the diagnosis and underlying cause is often delayed or overlooked. Homocystinuria, a rare autosomal recessive disorder is an identified risk factor for CVT.

Purpose: A timely diagnosis and treatment of the underlying cause of CVT could result in improved outcome and prevent further events. This case series describes the clinical course of six adults presented with unprovoked CVT, in whom the diagnosis of underlying homocystinuria was delayed with adverse consequences. We aim to highlight the importance of recognising homocystinuria as an underlying cause of CVT and offer a practical approach to the diagnosis and management.

Methods: This is a retrospective case series of a cohort of 30 consecutive patients seen in a UK tertiary referral centre.

Result: Six out of 30 patients presented with CVT prior to homocystinuria diagnosis. The mean and range of age at the time of the first CVT episode was 22.6 (range 11-31) years. The mean ±SD age at diagnosis of homocystinuria as the underlying cause was 26 ± 4.2 years. The time between first CVT and diagnosis of homocystinuria ranged from 1.6 to 11 years resulting in a delay to introduction of effective treatment and, in some cases, a further large vessels thrombotic event.

Conclusion: Physician awareness of homocystinuria as an underlying cause for an unprovoked CVT will facilitate timely introduction of effective treatment to prevent a further event.

Keywords: Sagittal sinus thrombosis; case series; cerebral venous thrombosis; homocystinuria; lens dislocation; pulmonary embolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Metabolic pathway of homocysteine. Homocysteine is produced through transmethylation of methionine. It is metabolised into cysteine by vitamin B6 (B6)–dependent cystathionine β-synthase (CBS). Remethylation of homocysteine to methionine occurs in a folate dependent pathway (that is catalysed by vitamin B12 (B12) dependent methionine synthase (MS) with involving folate dependent methylenetetrahydrofolate reductase (MTHFR)) or a folate independent pathway (that is catalysed by betaine-homocysteine methyltransferase (BHMT). 5-MTHF indicates 5-Methylenetetrahydrofolate; 5,10-MeTHF, 5,10-Methylenetetrahydrofolate; MT, Methyltransferase.
Figure 2.
Figure 2.
Proposed algorithm for selecting patients with First CVT to test for HCU and management. CVT, cerebral venous thrombosis; HCU, classical homocystinuria; tHcy, total homocysteine; URL, upper reference limit.

References

    1. Einhäupl K, Stam J, Bousser M-G, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229–1235. DOI: 10.1111/j.1468-1331.2010.03011.x. - DOI - PubMed
    1. Ferro JM, Bousser M-G, Canhão P, for the European Stroke Organisation , et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - Endorsed by the European Academy of Neurology. Eur Stroke J 2017; 2: 195–221. DOI: 10.1177/2396987317719364. - DOI - PMC - PubMed
    1. Idiculla PS, Gurala D, Palanisamy M, et al. Cerebral venous thrombosis: a comprehensive review. Eur Neurol 2020; 83: 369–379. DOI: 10.1159/00050980210.1159/000509802. - DOI - DOI - PubMed
    1. Behrouzi R, Punter M. Diagnosis and management of cerebral venous thrombosis. Clin Med 2018; 18: 75–79. DOI: 10.7861/clinmedicine.18-1-7510.7861/clinmedicine.18-1-75. - DOI - DOI - PMC - PubMed
    1. Ropper AH, Klein JP. Cerebral venous thrombosis. New Engl J Med 2021; 385: 59–64. DOI: 10.1056/NEJMra2106545. - DOI - PubMed

LinkOut - more resources